Home / Resources / Q3 2024 Highlights Report

Q3 2024 Highlights Report

Infographic
Commercial
Citeline professional presenting the Q3 2024 Outlook Report provided by Biomedtracker.

This roundup covers select catalysts from 24 drugs, devices, diagnostics, and deals expected to occur in Q3 2024. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Today’s approval is a testament to our population-specific strategy behind CAPVAXIVE, which demonstrated robust immunogenicity in a range of adult populations….
Merck
Related products
Expert analyst presenting data insights on a projected screen.
Biomedtracker
Real-time tracking and analysis of the drug development pipeline
Healthcare professionals using the latest and innovative medical device technology with 3D modeling.
Meddevicetracker
A 360° view of medical device markets, companies and products
Healthcare professional monitoring and analyzing R and D trends.
Pharmaprojects
The industry standard for tracking and analyzing the global drug R&D landscape

Related resources

''
Clinical

Pharma R&D Annual Review 2024

For over 30 years, the Pharma R&D Annual Review has tracked how the climate is shifting. Browse our resources to help you navigate the climate.

Q2 2024 Outlook Report
APR 08, 2024
Report
Commercial

Q2 2024 Outlook Report

Discover the catalysts, deals and likelihood of approval for 22 key drugs, devices and diagnostics expected to occur in Q2 2024.

Stacks of coins arranged in ascending order with a white arrow and line graph overlay indicating growth
JUN 11, 2024
eBook
Commercial

Billion Dollar Blueprint: The Journey to Blockbuster Status

A deep dive into the dynamics of blockbuster drugs. Using data from Evaluate Pharma, Scrip surveys the existing field of these top-tier products, examines the role that multiple indications play and the time it takes to reach blockbuster status, and considers whether there is an advantage for in-house or external assets.

View all